Leo O'Connor[email protected]Policy and RegulationPresident Biden launches $50M initiative to improve cancer outcomes in low-income areasThe award creates five Centers for Cancer Control Research in Persistent Poverty Areas to advance key priorities of the Administration’s Cancer Moonshot.June 26, 2023Payor CoverageReport shows Medicare risked up to $888M in improper payments for molecular pathology testThe HHS Office of Inspector General analyzed Medicare Part B claims associated with payments for more than 450,000 genetic tests billed under Current Procedural Terminology (CPT) code 81408.June 23, 2023Business InsightsWeek in Review: Quest to offer ctDNA MRD testing | Exact Sciences develops next-gen Cologuard | Detecting Candida aurisQuest Diagnostics completed its previously announced acquisition of Haystack Oncology, a developer of minimal-residual disease (MRD) testing technology.June 22, 2023Colorectal CancerNext-gen Cologuard demonstrates 94% sensitivity, 91% specificity for colorectal cancer detectionThe firm also entered collaborations related to next-generation technology for ultra-sensitive detection of molecular residual disease (MRD) and ongoing research, as well as for the development of its multicancer early detection (MCED) approach.June 21, 2023TuberculosisQiagen describes systematic review for IGRA TB test, blood collection tubesThe study including 4,050 subjects highlights the value of the TB2 tube and the detection of CD8 T-cell responses for immunocompromised patients, a key risk group for tuberculosis disease, the firm said.June 15, 2023Business InsightsWeek in Review: Biocartis layoffs | Predicting preeclampsia outcomes | Cystic fibrosis screeningRoche announced that its Cobas HPV test has been awarded WHO prequalification, expanding the cervical cancer screening tool's availability in countries that rely on the global organization’s list of prequalified suppliers to purchase tests.June 15, 2023Financial ResultsBiocartis to lay off 140 people in company reorganizationThe Mechelen, Belgium-based supplier of instruments and tests said the plan would reduce operating expenses by about 18 million euros annually.June 15, 2023Business InsightsWeek in Review: Molecular testing at home | C. auris detection from blood | ASCO presentationsAt-home testing got a boost this week when the FDA granted marketing authorization for the Cue Health COVID-19 Molecular Test.June 8, 2023SepsisPrenosis nabs $749K federal contract to study clinical utility of AI-based diagnostic tool for sepsisThe firm’s Sepsis ImmunoScore is a pathogen-agnostic, host-based digital diagnostic tool that uses artificial intelligence/machine learning to predict sepsis using clinical parameters and protein biomarkers.June 7, 2023Regulatory ApprovalCue Health granted first traditional FDA authorization for at-home test to detect respiratory illnessThe Cue COVID-19 Molecular Test detects genetic material from SARS-CoV-2 virus in nasal swabs from adults with signs and symptoms of upper respiratory infection.June 6, 2023Page 1 of 17Next PageTop StoriesPCRQiagen partners with FBI on forensics assayQiagen has announced a collaboration with the FBI to develop a new assay to improve DNA quantification for use in forensics and human identification.ImmunoassaysUniversity of Florida researchers develop CRISPR-based assay for HPV detectionFDA ClearanceGeneoscopy receives FDA approval for CRC screening testLawsuitGerman court rules patent invalid in 10x infringement suit against NanoStringSponsor ContentVisit our Molecular Diagnostics Community
